Therapy Areas: Oncology
Guardant Health partners with National Cancer Center East Japan for lung cancer liquid biopsy trials
13 March 2018 -

Cancer care company Guardant Health reported on Monday that its Guardant360 assay will be used as the sole liquid biopsy in LC-SCRUM-Japan, a nationwide genomic screening network run by the National Cancer Center Hospital East (NCCE) Kashiwa, Japan, to help lung cancer patients obtain access to approved drugs.

According to the company, Guardant360 is a comprehensive liquid biopsy that helps oncologists select the optimal treatment for advanced cancer patients without the need for an invasive tissue biopsy. The biopsy has been extensively validated, supported by 20 clinical outcome studies and is available in more than 30 countries.

Since 2003, LC-SCRUM-Japan has been screening patients for targeted therapies in Japan using tissue samples for genomic analysis. To date, more than 5,700 genetic screening tests have been performed and patients identified with genetic alterations have been enrolled in many targeted therapy clinical trials.

Guardant Health's new liquid biopsy arm is the first to include genomic analysis of blood samples through a comprehensive liquid biopsy. More than 1,000 samples will be collected in Japan and sent to Guardant Health's Redwood City lab for analysis.